Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009;11(1):1–11.

Article  Google Scholar 

Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20(5):849–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Rossum MAJ, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJW, Franssen MJAM, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66(11):1518–24.

Article  PubMed  PubMed Central  Google Scholar 

Lovell DJ, Johnson AL, Huang B, Gottlieb BS, Morris PW, Kimura Y, et al. Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease. Arthritis Rheumatol. 2018;70(9):1508–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis. 2015;74(2):381–8.

Article  CAS  PubMed  Google Scholar 

Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163–70.

Article  PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, et al. 2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–39.

Article  Google Scholar 

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.

Article  CAS  PubMed  Google Scholar 

Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;ard-2024–225531.

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613.

Article  PubMed  PubMed Central  Google Scholar 

Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res (2010). 2022;74(4):521–37.

Article  Google Scholar 

Horton DB, Salas J, Wec A, Kohlheim M, Kapadia P, Beukelman T, et al. Making decisions about stopping medicines for well-controlled juvenile idiopathic arthritis: a mixed-methods study of patients and caregivers. Arthritis Care Res (2010). 2021;73(3):374–85.

Article  Google Scholar 

Halyabar O, Mehta J, Ringold S, Rumsey DG, Horton DB. Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Paediatr Drugs. 2019;21(6):469–92.

Article  PubMed  PubMed Central  Google Scholar 

Markusse IM, Akdemir G, Huizinga TWJ, Allaart CF. Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients’ opinion. Clin Rheumatol. 2014;33(8):1155–9.

Article  CAS  PubMed  Google Scholar 

Uhrenholt L, Christensen R, Dinesen WKH, Liboriussen CH, Andersen SS, Dreyer L, et al. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology. 2022;61(8):3107–22.

Article  CAS  PubMed  Google Scholar 

Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.

Article  Google Scholar 

Veritas Health Innovation, Melbourne, Australia. Covidence. Covidence systematic review software. Available from: https://www.covidence.org/. Cited 2022 Jan 1.

Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) — Centre for Evidence-Based Medicine (CEBM), University of Oxford. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 Cited 2022 Dec 20.

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86.

Article  PubMed  PubMed Central  Google Scholar 

Emery P, Burmester GR, Naredo E, Sinigaglia L, Lagunes I, Koenigsbauer F, et al. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis. 2020;79(8):1023–30.

CAS  PubMed  Google Scholar 

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383(9914):321–32.

Article  CAS  PubMed  Google Scholar 

Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open. 2016;2(1):e000133.

Article  PubMed  PubMed Central  Google Scholar 

Van Mulligen E, Weel AE, Hazes JM, Van Der Helm-van MA, De Jong PHP. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79(9):1174–81.

Article  PubMed  Google Scholar 

Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, et al. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Res Ther. 2017;19(1):56.

Article  PubMed  PubMed Central  Google Scholar 

Sieper J. 118 - Management of ankylosing spondylitis/axial spondyloarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 6th ed. Philadelphia: Mosby; 2015. p. 970–85. https://www.sciencedirect.com/science/article/pii/B9780323091381001182. Cited 2023 Dec 4.

Chapter  Google Scholar 

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392(10142):134–44.

Article  PubMed  Google Scholar 

Wetterslev M, Georgiadis S, Sørensen IJ, Pedersen SJ, Christiansen SN, Hetland ML, et al. Tapering of TNF inhibitors in axial spondyloarthritis in routine care - 2-year clinical and MRI outcomes and predictors of successful tapering. Rheumatology (Oxford). 2022;61(6):2398–412.

PubMed  Google Scholar 

Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics. 2012;6:201–6.

CAS  PubMed  PubMed Central  Google Scholar 

Michielsens CA, Den Broeder N, Van Den Hoogen FH, Mahler EA, Teerenstra S, Van Der Heijde D, et al. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Ann Rheum Dis. 2022;81(10):1392–9.

Article  CAS  PubMed  Google Scholar 

Gratacós J, Pontes C, Juanola X, Sanz J, Torres F, Avendaño C, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):11.

Article  PubMed  PubMed Central  Google Scholar 

Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290–4.

Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, Alliance (CARRA) CARR, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(7):929–36.

Article  Google Scholar 

Papailiou S, Dasoula F, Tsolia MN, Maritsi DN. Attainment of inactive disease following discontinuation of adalimumab monotherapy in patients with enthesitis-related arthritis: a real-life, Dual-Center Experience. J Clin Rheumatol. 2022;28(2):e616–8.

Article  PubMed  Google Scholar 

Liao CH, Chiang BL, Yang YH. Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice. Front Med. 2021;8. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2021.665170. Cited 2022 Aug 22.

El Miedany Y, El Gaafary M, Youssef S, Ahmed I, Bahlas S, Hegazi M, et al. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35(12):2915–23.

Article